{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:37:30Z","timestamp":1793191050897,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T00:00:00Z","timestamp":1553558400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GSK","award":["Study: 209304; NCT01313637\/NCT01313650"],"award-info":[{"award-number":["Study: 209304; NCT01313637\/NCT01313650"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12931-019-1027-9","type":"journal-article","created":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T11:03:02Z","timestamp":1553598182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2263-1407","authenticated-orcid":false,"given":"Ian","family":"Naya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Tombs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Lipson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Boucot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Compton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,26]]},"reference":[{"key":"1027_CR1","volume-title":"Management and prevention of chronic obstructive pulmonary disease","author":"Global Initiative for chronic Obstructive Lung Disease (GOLD)","year":"2019","unstructured":"Global Initiative for chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis. In:  Management and prevention of chronic obstructive pulmonary disease; 2019."},{"key":"1027_CR2","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1183\/09031936.00195212","volume":"42","author":"A Agusti","year":"2013","unstructured":"Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J. 2013;42:636\u201346.","journal-title":"Eur Respir J"},{"key":"1027_CR3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S2213-2600(18)30002-X","volume":"6","author":"A Gedebjerg","year":"2018","unstructured":"Gedebjerg A, Szepligeti SK, Wackerhausen LH, et al. Prediction of mortality in patients with chronic obstructive pulmonary disease with the new global initiative for chronic obstructive lung disease 2017 classification: a cohort study. Lancet Respir Med. 2018;6:204\u201312.","journal-title":"Lancet Respir Med"},{"key":"1027_CR4","volume-title":"Management and prevention of chronic obstructive pulmonary disease","author":"Global Initiative for chronic Obstructive Lung Disease (GOLD)","year":"2011","unstructured":"Global Initiative for chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis. In:  Management and prevention of chronic obstructive pulmonary disease; 2011."},{"key":"1027_CR5","first-page":"381","volume":"11","author":"PM Calverley","year":"2016","unstructured":"Calverley PM, Postma DS, Anzueto AR, et al. Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations. Int J COPD. 2016;11:381\u201390.","journal-title":"Int J COPD"},{"key":"1027_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.pupt.2017.12.005","volume":"49","author":"JF Donohue","year":"2018","unstructured":"Donohue JF, Jones PW, Bartels C, et al. Correlations between FEV1 and patient-reported outcomes: a pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2018;49:11\u20139.","journal-title":"Pulm Pharmacol Ther"},{"key":"1027_CR7","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.chest.2017.04.174","volume":"152","author":"AD Zider","year":"2017","unstructured":"Zider AD, Wang X, Buhr RG, et al. Reduced COPD exacerbation risk correlates with improved FEV1: a meta-regression analysis. Chest. 2017;152:494\u2013501.","journal-title":"Chest."},{"key":"1027_CR8","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.chest.2016.02.646","volume":"149","author":"L Calzetta","year":"2016","unstructured":"Calzetta L, Rogliani P, Matera MG, et al. A systematic review with meta-analysis of dual bronchodilation with LAMA\/LABA for the treatment of stable COPD. Chest. 2016;149:1181\u201396.","journal-title":"Chest."},{"key":"1027_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.rmed.2016.01.001","volume":"112","author":"JF Donohue","year":"2016","unstructured":"Donohue JF, Singh D, Munzu C, et al. Magnitude of umeclidinium\/vilanterol lung function effect depends on monotherapy responses: results from two randomised controlled trials. Respir Med. 2016;112:65\u201374.","journal-title":"Respir Med"},{"key":"1027_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/thoraxjnl-2014-206732","volume":"71","author":"Y Oba","year":"2016","unstructured":"Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting beta-agonist\/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016;71:15\u201325.","journal-title":"Thorax."},{"key":"1027_CR11","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1183\/09031936.00200212","volume":"42","author":"ED Bateman","year":"2013","unstructured":"Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42:1484\u201394.","journal-title":"Eur Respir J"},{"key":"1027_CR12","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1183\/09031936.00136014","volume":"45","author":"R Buhl","year":"2015","unstructured":"Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2\u20134). Eur Respir J. 2015;45:969\u201379.","journal-title":"Eur Respir J"},{"key":"1027_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S2213-2600(18)30102-4","volume":"6","author":"PMA Calverley","year":"2018","unstructured":"Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6:337\u201344.","journal-title":"Lancet Respir Med"},{"key":"1027_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","volume":"1","author":"JA Wedzicha","year":"2013","unstructured":"Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1:199\u2013209.","journal-title":"Lancet Respir Med"},{"key":"1027_CR15","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2147\/COPD.S102494","volume":"11","author":"G Feldman","year":"2016","unstructured":"Feldman G, Maltais F, Khindri S, et al. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 \u03bcg compared with tiotropium 18 \u03bcg in patients with COPD. Int J COPD. 2016;11:719\u201330.","journal-title":"Int J COPD"},{"key":"1027_CR16","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1007\/s12325-017-0626-4","volume":"34","author":"GJ Feldman","year":"2017","unstructured":"Feldman GJ, Sousa AR, Lipson DA, et al. Comparative efficacy of once-daily Umeclidinium\/Vilanterol and tiotropium\/Olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a randomized study. Adv Ther. 2017;34:2518\u201333.","journal-title":"Adv Ther"},{"key":"1027_CR17","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s41030-017-0048-0","volume":"3","author":"KYJ Sion","year":"2017","unstructured":"Sion KYJ, Huisman EL, Punekar YS, et al. A network meta-analysis of long-acting muscarinic antagonist (LAMA) and long-acting \u03b22-agonist (LABA) combinations in COPD. Pulm Ther. 2017;3:297\u2013316.","journal-title":"Pulm Ther"},{"key":"1027_CR18","doi-asserted-by":"publisher","first-page":"545","DOI":"10.7326\/0003-4819-146-8-200704170-00152","volume":"146","author":"SD Aaron","year":"2007","unstructured":"Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146:545\u201355.","journal-title":"Ann Intern Med"},{"key":"1027_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12890-015-0077-0","volume":"15","author":"CR Jenkins","year":"2015","unstructured":"Jenkins CR, Postma DS, Anzueto AR, et al. Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease. BMC Pulm Med. 2015;15:97.","journal-title":"BMC Pulm Med"},{"key":"1027_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/13696998.2016.1223085","volume":"20","author":"YS Punekar","year":"2017","unstructured":"Punekar YS, Naya I, Small M, et al. Bronchodilator reliever use and its association with the economic and humanistic burden of COPD: a propensity-matched study. J Med Econ. 2017;20:28\u201336.","journal-title":"J Med Econ"},{"key":"1027_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12931-017-0566-1","volume":"18","author":"YS Punekar","year":"2017","unstructured":"Punekar YS, Sharma S, Pahwa A, et al. Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis. Respir Res. 2017;18:86.","journal-title":"Respir Res"},{"key":"1027_CR22","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1378\/chest.13-1579","volume":"145","author":"B Celli","year":"2014","unstructured":"Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium\/vilanterol 125\/25 mcg in COPD: a randomized, controlled study. Chest. 2014;145:981\u201391.","journal-title":"Chest."},{"key":"1027_CR23","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.rmed.2013.06.001","volume":"107","author":"JF Donohue","year":"2013","unstructured":"Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium\/vilanterol 62.5\/25 mcg in COPD. Respir Med. 2013;107:1538\u201346.","journal-title":"Respir Med"},{"key":"1027_CR24","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1183\/09031936.04.00014304","volume":"23","author":"BR Celli","year":"2004","unstructured":"Celli BR, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper. Eur Respir J. 2004;23:932.","journal-title":"Eur Respir J"},{"key":"1027_CR25","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1124\/pr.111.004580","volume":"64","author":"M Cazzola","year":"2012","unstructured":"Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64:450\u2013504.","journal-title":"Pharmacol Rev"},{"key":"1027_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1164\/rccm.201609-1794CI","volume":"196","author":"KM Beeh","year":"2017","unstructured":"Beeh KM, Burgel PR, Franssen FME, et al. How do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 2017;196:139\u201349.","journal-title":"Am J Respir Crit Care Med"},{"key":"1027_CR27","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1183\/09031936.00048912","volume":"40","author":"JA Wedzicha","year":"2012","unstructured":"Wedzicha JA, Decramer M, Seemungal TAR. The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J. 2012;40:1545.","journal-title":"Eur Respir J"},{"key":"1027_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.pupt.2012.07.003","volume":"26","author":"H Meurs","year":"2013","unstructured":"Meurs H, Dekkers BG, Maarsingh H, et al. Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulm Pharmacol Ther. 2013;26:145\u201355.","journal-title":"Pulm Pharmacol Ther"},{"key":"1027_CR29","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S2213-2600(13)70158-9","volume":"1","author":"ML Decramer","year":"2013","unstructured":"Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013;1:524\u201333.","journal-title":"Lancet Respir Med"},{"key":"1027_CR30","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1056\/NEJMoa1008378","volume":"364","author":"C Vogelmeier","year":"2011","unstructured":"Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364:1093\u2013103.","journal-title":"N Engl J Med"},{"key":"1027_CR31","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.rmed.2014.10.002","volume":"108","author":"MR Maleki-Yazdi","year":"2014","unstructured":"Maleki-Yazdi MR, Kaelin T, Richard N, et al. Efficacy and safety of umeclidinium\/vilanterol 62.5\/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108:1752\u201360.","journal-title":"Respir Med"},{"key":"1027_CR32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12931-016-0387-7","volume":"17","author":"D Singh","year":"2016","unstructured":"Singh D, Gaga M, Schmidt O, et al. Effects of tiotropium\u2009+\u2009olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO\u00ae studies. Respir Res. 2016;17:73.","journal-title":"Respir Res"},{"key":"1027_CR33","doi-asserted-by":"crossref","unstructured":"Alc\u00e1zar Navarrete B, Boucot I, Naya I, et al. Umeclidinium\/Vilanterol versus tiotropium\/Olodaterol in maintenance-Na\u00efve patients with moderate symptomatic chronic obstructive pulmonary disease: a post hoc analysis. Pulm Ther. 2018.","DOI":"10.1007\/s41030-018-0057-7"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-019-1027-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12931-019-1027-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-019-1027-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T00:07:30Z","timestamp":1585094850000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-019-1027-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,26]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1027"],"URL":"https:\/\/doi.org\/10.1186\/s12931-019-1027-9","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,26]]},"assertion":[{"value":"30 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All clinical studies included in this pooled analysis were carried out according to the principles of the Declaration of Helsinki and received appropriate ethical approval. Informed consent was obtained for all individual participants included in the studies used as the basis for this pooled analysis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IN, DAL, IB, and CC are employees of GSK and hold stocks and shares in GSK. LT is a contingent worker on assignment at GSK. ELLIPTA is owned by\/licensed to the GlaxoSmithKline group of companies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"60"}}